Mild Cognitive Impairment

Sorry, no news articles match your request. Your search criteria may be too narrow.

Mild cognitive impairment (MCI, also known as incipient dementia, or isolated memory impairment) is a brain-function syndrome involving the onset and evolution of cognitive impairments beyond those expected based on the age and education of the individual, but which are not significant enough to interfere with their daily activities. It is often found to be a transitional stage between normal aging and dementia. Although MCI can present with a variety of symptoms, when memory loss is the predominant symptom it is termed "amnestic MCI" and is frequently seen as a prodromal stage of Alzheimer's disease. Studies suggest that these individuals tend to progress to probable Alzheimer’s disease at a rate of approximately 10% to 15% per year.

Additionally, when individuals have impairments in domains other than memory it is classified as non-amnestic single- or multiple-domain MCI and these individuals are believed to be more likely to convert to other dementias (e.g. dementia with Lewy bodies). However, some instances of MCI may simply remain stable over time or even remit. Causation of the syndrome in and of itself remains unknown, as therefore do prevention and treatment.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Popular antioxidant likely ineffective, study finds

The popular dietary supplement ubiquinone, also known as Coenzyme Q10, is widely believed to function as an antioxidant, protecting cells against damage from free radicals. But a new study by scientists at McGill University ...

Research suggests brain's melatonin may trigger sleep

If you walk into your local drug store and ask for a supplement to help you sleep, you might be directed to a bottle labeled "melatonin." The hormone supplement's use as a sleep aid is supported by anecdotal ...

New understanding of stroke damage may aid recovery

Stroke can lead to a wide range of problems such as depression and difficulty moving, speaking and paying attention. Scientists have thought these issues were caused by damage to the brain's "computer processors"—cells ...

FDA approves first lower-cost biotech drug (Update)

Federal health officials have approved the first lower-cost copy of a biotech drug to reach the U.S. market, a long-awaited milestone that could generate billions in savings for insurers, doctors and patients.